The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.

Robinson PC., Liew DFL., Liew JW., Monaco C., Richards D., Shivakumar S., Tanner HL., Feldmann M.

Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arthritis, TNF blockade reduces not only biologically active TNF but other pro-inflammatory cytokines important in COVID-19 hyperinflammation. Observational data from patients already on anti-TNF therapy show a reduced rate of COVID-19 poor outcomes and death compared with other immune-suppressing therapies. Anti-TNF has a long history of safe use, including in special at-risk populations, and is widely available. The case to adequately assess anti-TNF as a treatment for COVID-19 is compelling.

DOI

10.1016/j.medj.2020.11.005

Type

Journal article

Journal

Med (N Y)

Publication Date

18/12/2020

Volume

1

Pages

90 - 102

Keywords

SARS-CoV-2, coronavirus disease-2019, glucocorticoids, pandemic, tumor necrosis factor

Permalink Original publication